Funding & Industry Engagement

Adelaide Enterprise connects University of Adelaide researchers with Industry and funding opportunities.


Adelaide Enterprise aims to bridge the funding gap for researchers engaged in research that has potential for translation to commercial impact.

Engage with us early, so we can assist you from the moment of discovery, through planning, setting a commercialisation strategy and finally delivering your product or service to market.

Adelaide Enterprise services are provided free to University of Adelaide researchers.

  • IP Group

    Support for new inventions by IP Group

    The University of Adelaide, along with the other Group of Eight Universities and the University of Auckland announced in May that they will be the exclusive beneficiaries in a $200m venture fund established by the IP Group.

    IP Group was founded in 2001, to commercialise technologies from the Chemistry Department at the University of Oxford. Since that time, it has added about one university a year to its partnership model. Such universities include King’s College, London, Manchester and Leeds. It has also acquired a number of similar companies across the UK.

    In 2013 IP Group raised £100m to enter the US market and established offices locally.  It has partnerships with Columbia, Princeton, the University of Pennsylvania, the University of Washington and three research labs. IP Group is looking to reproduce that model in Australia through the Go8.

    IPG’s business model is to create deep and long term collaborations with research institutions to access and nurture immature technologies to a stage where they are investable by the venture and finance community. IPG provides mentorship, business services and networks for its investee companies, thus giving them a better foundation for success.

    IPG’s strengths are in Healthcare, Technology, Cleantech and Biotech. Its portfolio companies announce capital raisings once every couple of months and can range from £1m to over £100m (Oxford Nanopore Dec 2016). In the first half of 2016 its portfolio companies raised £38m, IPG made new investments of £12.8m and the total value of the portfolio was £525.7m.

    As a priority investment partner in new start up’s, the University is required to present IP Group with all unencumbered (not previously partnered through prior research collaborations and IP exclusively owned by the University) new invention disclosures and provide IP Group with a first right of refusal, thus early notification is highly encouraged.

    If you are interested in presenting a technology to the IP Group, please complete the IPG template and email to or talk to one of our Commercial Managers.

    If you are seeking to submit a full invention disclosure, please continue to use the invention disclosure form.

    IP Group's focus areas


    “IP Cleantech finds, funds and builds outstanding, science-based businesses that mitigate the impacts of climate change and other environmental challenges.”

    • Happy to do very early-stage
    • Interested in
      • Asset productivity (SW / Project optimisation)
      • Grid integration / distributed power
      • Utilisation of satellite imagery for asset utilisation
      • Energy Storage
      • Energy efficiency is in vogue! i.e. IoT utilisation
      • Water (cleanliness / purification / removal of plastics / membranes)
      • Low energy ICT
      • Traffic forecasting
    • Unlikely to do
      • Ideas requiring large amounts of capital (i.e. submarine power generation / wave power)
      • Any new battery chemistry
      • Desalination
      • Transport (no drivetrain)


    “The aim of the Technology division is to “shape the future” by commercialising innovative technologies derived from our partner research institutions. The division covers a broad spectrum of scientific fields from advanced materials, through the various disciplines of chemical, mechanical, electrical and electronic engineering, to information and communications technologies, including both hardware and software.”

    • Interested in
      • Physical chemistry
      • Advanced materials
      • Mechanical Engineering
      • Electrical Engineering
      • Photonics & Communications
      • SW & ITC
      • Emotional Detection
      • Human-like interaction
      • Quantum computing
      • Next Gen Networks / SW defined networks
      • Augmented Reality
    • Less interested in
      • Pure materials
      • Photonics components


    “The aim of the Biotech division is to support the discovery and development of breakthrough therapeutics, achieved either by in-house development of proprietary products licensed directly into the Group or via the more conventional development and financing of portfolio companies.”


    “IP Healthcare finds and supports innovations to improve health outcomes and that are sustainable in a world where the funding of healthcare is subject to fundamental change.”

  • Commercial Accelerator Scheme (CAS)

    Providing a cash injection for early stage inventions and services.

    *Applications for the next round of CAS funding will open mid-2019. Please email with any specific enquiries or learn more about our 2018 recipients here.

    The Commercial Accelerator Scheme is a competitive, internal funding program, managed by the University’s commercialisation team, Adelaide Enterprise.

    The Scheme funds the development of innovations at all stages of the commercial pipeline to the point where they can be commercialised as new products, services and companies (this is not funding for basic research).

    The scheme offers up to $100,000 per project, in grant or equity funding for eligible projects seeking financial support for commercialisation activities and translation of research.

    Applications are assessed by an external panel, based on Quality of Research Proposal, Commercial Readiness and Impact.

    Applicants must engage with an Adelaide Enterprise Commercialisation Manager to work up their applications in order to be eligible to apply.

    Successful recipients will be announced at Adelaide Enterprise’ end of year function in December.

  • Medical Research Commercialisation Fund

    The Medical Research Commercialisation Fund (MRCF), managed by Brandon Capital, is an innovative investment collaboration which invests in life science opportunities from its member medical research institutes and their associated hospitals throughout Australia. The MRCF has $200m of funding available from Australian superannuation funds, to invest in early stage technologies. The Fund also provides valuable commercialisation advice to its 50 member institutes.

    The Robinson Research Institute is the University of Adelaide’s member institute for the fund. Projects considered for funding by the MRCF need to show a benefit back to the Robinson Research Institute.

    • Melissa McBurnie, from Brandon Capital, is the South Australian representative for the MRCF.
    • Jeremy Thompson is the University’s representative for the MRCF. Please contact Jeremy if you would like to present your project to Melissa for consideration by the MRCF.
  • Techstars

    Global accelerator program Techstars has come to Adelaide, and is now inviting applications for early stage companies to participate in their 12 week accelerator program. Eligible companies must be advancing technologies to benefit the defence and security sectors, across either:

    • Internet of Things (IoT)
    • Big data
    • Sensors and robotics

    Please contact Adelaide Enterprise if you would like to apply to participate in the program.

  • Ximbio reagents partnership

    Want to share a reagent that you have created?

    The university has partnered with Ximbio to promote and commercialise reagents owned by the University.

    This is a great opportunity to share what you have created with other researchers and companies that are working in your area and to potentially create new research relationships. Let people know what you do by sharing what you have created.

    Please email to discuss your reagent with one of our Commercial Managers.